JMP Securities Analyst Initiates Coverage on Acrivon Therapeutics with Market Outperform Rating and 14 Target Price
On March 2, 2024, Silvan Tuerkcan, an analyst at JMP Securities, began covering Acrivon Therapeutics (NASDAQ: ACRV) with an optimistic ...